

Atty. Docket No. PU496

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of KAZMIERSKI et al.

International Application No.: PCT/US2003/039644

International Filing Date: December 12, 2003

For: CCR5 Antagonists as Therapeutic Agents

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

 Copies of the references are enclosed Copies of the references were submitted in parent application Serial No. _____.
(37 CFR 1.98(d)) A copy of the International Search Report which issued on International Application No. PCT/US2003/039644 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

 The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:


- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

Express Mail Label No.: EV332065690US

Date of Mailing: 6/19/05

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.



Patty Wilson

10538144

Atty. Docket No. PU496

JC12 R6 PCT/PTC 09 JUN 2005

[] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

[] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

C. [] The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

[] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**

[] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and

[] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,


Bonnie L. Deppenbrock
Attorney of Record
Registration No. 28,209

Date: 9 June 2005

Customer No. 23347

GlaxoSmithKline

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-1577

Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	SERIAL NO.	
	FILING DATE	
	APPLICANT	Kazmierski et al.
	GROUP	
	EXAMINER	
	ATTORNEY DOCKET NO.	PU4962USw

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	2,773,870	12/11/1956	Elpern			
	2.	2,248,018	7/1/1941	Eisleb			
	3.	3,539,580	11/10/1970	Hermans Hubert Karel Frans et al.			
	4.	3,334,106	8/1/1967	Biel			
	5.	5,340,822	8/23 1994	Emonds-Alt Zavier et al.			

Continue on page

FOREIGN PATENT DOCUMENTS

Continue on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

12. REHSE et al., Platelet aggregation inhibiting and anticoagulant effects of oligamines, *Archiv Der Pharmazie*, VCH Verlagsgesellschaft MBH, Weinheim, DE 319:505-515 (1986).

13. STEVENTON et al., 4,4-disubstituted Piperidine High-Affinity NK1 Antagonists: Structure-Activity Relationships in vivo Activity, *J. of Medicinal Chem.* 41(23):4623-4622 (1998).

14. Database WPI Section Ch, Week 2003335, XP002283279.

15. WHITTENBERGER et al., Dialkyltin Oxide Mediated Addition of Trimethylsilyl Azide to Nitriles. A Novel Preparation of 5-Substituted Tetrazoles, *J. Org. Chem.* 58:4139-4141 (1993).

16. KOHARA et al., Synthesis and Angiotensin II Receptor Antagonistic Activities of Benzimidazole Derivatives Bearing Acidic Heterocycles as Novel Tetrazole Bioisosteres, *J. Med. Chem.* 39:5228-5235 (1996).

17. TYLE, Iontophoretic Devices for Drug Delivery, *Pharmaceutical Research* 3(6):318-326 (1986).

Continue on page

EXAMINER _____ DATE CONSIDERED _____
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.